A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF).

Trial Profile

A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2013

At a glance

  • Drugs AZD 0837 (Primary) ; Warfarin
  • Indications Embolism; Stroke
  • Focus Therapeutic Use
  • Acronyms ASSURE-AF
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Jun 2012 Additional location (Slovakia) added as reported by European Clinical Trials Database.
    • 07 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top